aTyr Pharma expands at-the-market equity facility with Jefferies after exhausting prior $65M capacity

aTYR PHARMA INC

On Dec 23, 2024, amended Open Market Sale Agreement with Jefferies to allow additional common stock sales.
Prior aggregate offering amount of $65M under the Sales Agreement was fully sold as of the amendment date.
New shares may be sold at the market; amount governed by prospectus supplement filed December 23, 2024.
Original terms and conditions of the Sales Agreement remain unchanged; Jefferies will use commercially reasonable efforts.
Issuance will be made under effective registration statement on Form S-3 (File No. 333-275455).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.